Related Experiment Video

Updated: May 22, 2026

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation

Yong Hannah Wen1, Alice Ho, Sujata Patil

  • 1Department of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. weny@mskcc.org

Breast Cancer Research and Treatment
|April 28, 2012
PubMed

Insights

Id4 protein is highly expressed in most triple-negative breast carcinomas (TNBCs), potentially impairing BRCA1 pathway function. This finding is crucial for understanding TNBC development and exploring new therapeutic targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Germline BRCA1 mutations are typically associated with ER, PR, and HER2 negative breast cancer.
  • Somatic BRCA1 mutations are infrequent in sporadic breast cancers, but functional impairment can occur through other mechanisms, especially in triple-negative breast carcinomas (TNBCs).
  • Id4, a DNA binding factor, is known to inhibit BRCA1 gene transcription in vitro and may downregulate BRCA1 in vivo.

Purpose of the Study:

  • To compare Id4 immunoreactivity in TNBCs versus non-TNBCs.
  • To correlate Id4 expression with tumor morphology and markers like CK5/6, CK14, EGFR, and androgen receptor (AR).
  • To investigate the potential role of Id4 in functional downregulation of BRCA1 pathways in TNBCs.

Main Methods:

  • Immunohistochemical analysis of Id4 expression in 101 TNBCs and 113 non-TNBCs.
  • Correlation of Id4 immunoreactivity with histological grade, mitotic rate, and markers including CK5/6, CK14, EGFR, and AR.
  • Evaluation of Id4 expression in TNBCs with specific morphological features, such as central necrosis.

Main Results:

  • Id4 was significantly overexpressed in 75% of TNBCs compared to only 5% of non-TNBCs (p < 0.0001).
  • Id4 expression correlated strongly with high histologic grade (p = 0.0002), high mitotic rate (p = 0.006), and CK14 reactivity (p < 0.0001).
  • Id4 was notably present in TNBCs exhibiting large central acellular zones of necrosis and was largely absent in apocrine carcinomas.

Conclusions:

  • Substantial Id4 expression is a common feature in most TNBCs.
  • Id4 upregulation may contribute to the functional downregulation of BRCA1 pathways in TNBCs.
  • These findings highlight Id4 as a potential biomarker and therapeutic target in TNBC.

More Related Videos

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...